Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.
Cancers infiltrated with T-cells are associated with a higher likelihood of response to PD-1/PD-L1 blockade. Counterintuitively, a correlation between epithelial-mesenchymal transition (EMT)-related gene expression and T-cell infiltration has been observed across tumor types. Here we demonstrate, using The Cancer Genome Atlas (TCGA) urothelial cancer dataset, that although a gene expression-based measure of infiltrating T-cell abundance and EMT-related gene expression are positively correlated, these signatures convey disparate prognostic information. We further demonstrate that non-hematopoietic stromal cells are a major source of EMT-related gene expression in bulk urothelial cancer transcriptomes. Finally, using a cohort of patients with metastatic urothelial cancer treated with a PD-1 inhibitor, nivolumab, we demonstrate that in patients with T-cell infiltrated tumors, higher EMT/stroma-related gene expression is associated with lower response rates and shorter progression-free and overall survival. Together, our findings suggest a stroma-mediated source of immune resistance in urothelial cancer and provide rationale for co-targeting PD-1 and stromal elements.
浸润 T 细胞的癌症与对 PD-1/PD-L1 阻断的反应可能性更高相关。反直觉的是,在肿瘤类型之间观察到上皮-间充质转化(EMT)相关基因表达与 T 细胞浸润之间存在相关性。在这里,我们使用癌症基因组图谱(TCGA)的尿路上皮癌数据集证明,尽管基于基因表达的浸润 T 细胞丰度和 EMT 相关基因表达的衡量标准呈正相关,但这些特征传达了不同的预后信息。我们进一步证明,非造血基质细胞是大量尿路上皮癌转录组中 EMT 相关基因表达的主要来源。最后,使用接受 PD-1 抑制剂nivolumab 治疗的转移性尿路上皮癌患者队列,我们证明在 T 细胞浸润的肿瘤患者中,较高的 EMT/基质相关基因表达与较低的反应率以及较短的无进展生存期和总生存期相关。总之,我们的研究结果表明尿路上皮癌中存在基质介导的免疫抵抗源,并为同时靶向 PD-1 和基质成分提供了依据。